Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5198792
Max Phase: Preclinical
Molecular Formula: C23H27ClN2O4
Molecular Weight: 430.93
Associated Items:
ID: ALA5198792
Max Phase: Preclinical
Molecular Formula: C23H27ClN2O4
Molecular Weight: 430.93
Associated Items:
Canonical SMILES: NC(=O)c1ccc(C(=O)OCCCCN2CCC(O)(c3ccc(Cl)cc3)CC2)cc1
Standard InChI: InChI=1S/C23H27ClN2O4/c24-20-9-7-19(8-10-20)23(29)11-14-26(15-12-23)13-1-2-16-30-22(28)18-5-3-17(4-6-18)21(25)27/h3-10,29H,1-2,11-16H2,(H2,25,27)
Standard InChI Key: VVWAEFSEWWHXPN-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 430.93 | Molecular Weight (Monoisotopic): 430.1659 | AlogP: 3.36 | #Rotatable Bonds: 8 |
Polar Surface Area: 92.86 | Molecular Species: BASE | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.53 | CX Basic pKa: 9.00 | CX LogP: 2.99 | CX LogD: 1.39 |
Aromatic Rings: 2 | Heavy Atoms: 30 | QED Weighted: 0.49 | Np Likeness Score: -0.68 |
1. Dichiara M, Artacho-Cordón A, Turnaturi R, Santos-Caballero M, González-Cano R, Pasquinucci L, Barbaraci C, Rodríguez-Gómez I, Gómez-Guzmán M, Marrazzo A, Cobos EJ, Amata E.. (2022) Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation., 230 [PMID:35016113] [10.1016/j.ejmech.2021.114091] |
Source(1):